Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2001

View Archived Issues

Current enrollment accelerating in Emisphere's phase III oral heparin program

Tanox opens enrollment for phase I trial of TNX-355 for HIV

GC-C agonists inhibit colon cancer cell proliferation

Texas Biotechnology announces approval of argatroban in Canada

Early c-Fos induction appears to have neuroprotective role in cerebral ischemia

Phase I trial of oral gluconeogenesis inhibitors for diabetes mellitus set to begin

Long-terms effects of Ac-SDKP assessed in rat model of renovascular hypertension

FDA approves DuPont Pharmaceutical's ultrasound contrast agent Definity

Abbott Laboratories submits NDA for Synthroid ahead of schedule

Novel leukemia drug receives positive opinion from CPMP

Polydex reports latest advancements for development of Usherdex for lung disorders

Letrozole may increase adult height in boys with delayed puberty

ViroPharma files NDA for pleconaril for the treatment of viral respiratory infection in adults

Phase II trial of ABX-EGF for non-small cell lung cancer initiated

Corixa receives milestone payment for lung cancer vaccine

Patient enrollment completed in Xcytrin phase II clinical trial for glioblastoma multiforme

Memantine to be evaluated in the treatment of diabetic neuropathy

Use of beta-adrenoceptor antagonists for treating outer retina disorders described

Ono Pharmaceutical presents a new series of cysteine protease inhibitors

VLA-4 integrin antagonists presented by Novartis

Novel adamantane derivatives and their use described by AstraZeneca

Compounds useful for the treatment of chronic inflammatory diseases patented by F. Hoffmann-La Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...